Paramora Holding LLC owns 2,045,473 shares — Damora (NASDAQ: DMRA)

Rhea-AI Filing Summary

Damora Therapeutics, Inc. ownership filing: Paramora Holding LLC reports beneficial ownership of 2,045,473 shares of Common Stock, representing 3.39% of the class. The filing cites 60,303,212 shares outstanding as of March 17, 2026 and is signed on April 23, 2026.

The filing is an amendment to a Schedule 13G, noting ownership and voting/dispositive powers (sole voting power 2,045,473, sole dispositive power 2,045,473), and states the position is 5% or less of the class.

Key Figures

Shares beneficially owned: 2,045,473 shares Percent of class: 3.39% Shares outstanding (as of): 60,303,212 shares +2 more

5 metrics

Shares beneficially owned 2,045,473 shares reported by Paramora Holding LLC in Schedule 13G/A

Percent of class 3.39% based on 60,303,212 shares outstanding as of March 17, 2026

Shares outstanding (as of) 60,303,212 shares outstanding as of March 17, 2026 (issuer 10-K citation)

CUSIP 36322Q206 Damora Therapeutics Common Stock CUSIP on cover page

Signature date 04/23/2026 filing signed by Keri Lantz, Treasurer

Key Terms

Schedule 13G/A, Beneficially owned, Sole voting power, Sole dispositive power

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) Damora Therapeutics, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Amount beneficially owned: See the response to Item 9"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole voting power regulatory

"Sole Voting Power 2,045,473.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole dispositive power regulatory

"Sole Dispositive Power 2,045,473.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Damora Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

36322Q206

(CUSIP Number)

02/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 36322Q206

1

Names of Reporting Persons

Paramora Holding LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,045,473.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,045,473.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,045,473.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.39 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Row 11 is based on 60,303,212 shares of Common Stock outstanding as of March 17, 2026 as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on March 19, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Damora Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453
Item 2.
(a)	Name of person filing: Paramora Holding LLC
(b)	Address or principal business office or, if none, residence: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 36322Q206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response to Item 9 on the attached cover page.
(b)	Percent of class: See the response to Item 11 on the attached cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response to Item 5 on the attached cover page.
	(ii) Shared power to vote or to direct the vote: See the response to Item 6 on the attached cover page.
	(iii) Sole power to dispose or to direct the disposition of: See the response to Item 7 on the attached cover page.
	(iv) Shared power to dispose or to direct the disposition of: See the response to Item 8 on the attached cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paramora Holding LLC

Signature:	/s/ Keri Lantz
Name/Title:	Keri Lantz, Treasurer
Date:	04/23/2026

FAQ

What stake does Paramora Holding LLC report in Damora Therapeutics (DMRA)?

Paramora Holding LLC reports beneficial ownership of 2,045,473 shares, equal to 3.39% of the class. The percentage is calculated using 60,303,212 shares outstanding as of March 17, 2026 per the cited annual report.

Does the Schedule 13G/A show voting or dispositive power for Paramora (DMRA)?

Yes. The filing lists sole voting power of 2,045,473 shares and sole dispositive power of 2,045,473 shares. No shared voting or shared dispositive power is reported in the provided excerpt.

Is Paramora's position considered a control stake in DMRA?

No. The filing indicates ownership of 3.39%, which is below the 5% threshold and the filing itself states ownership of 5% or less. The report does not assert control of the company.

When was the Schedule 13G/A for DMRA signed and filed by Paramora?

The filing excerpt is signed by Keri Lantz, Treasurer on April 23, 2026. The cover page references outstanding shares as of March 17, 2026 from the issuer's annual report.